Buy Human Growth Hormone Supplements, HGH Supplements
Doctor's "PATENTED" Growth Hormone Triple Strength is a revolutionary, all natural herbal growth hormone potentiator, that is the result of combining thousands of years of Ayurvedic (the oldest recorded form of medicine in the world) herbal experience with the latest breakthroughs in modern technology. This special, patented synergistic blend of herbal extracts, combined with a unique delivery system, produces a very potent and extremely effective growth hormone (GH) enhancer. Triple Strength Growth Hormone is rated number one by leading industry experts. This remarkable patented formula is the ONLY product listed under GROWTH HORMONE THERAPY, page 713 in the world renowned manual “Prescription for Nutritional Healing” by Phyllis A. Balch, CNC and James F. Balch, M.D. (3rd Edition). “Prescription for Nutritional Healing” is considered by the industry as the most factual, exacting, and reputable natural health manual available. Doctor's Growth Hormone Triple Strength is listed in every edition since the 3rd edition as they only recommended herbal growth hormone supplement. You can’t buy your Growth Hormone Supplement into this book. Doctor’s Growth Hormone Supplement being the only one that has ever been in this book shows just how good this supplement is.
Compare Doctor's Triple Strength Growth Hormone to the synthetic injectable forms of growth hormone and you will be quite impressed. Synthetic injectable growth hormone requires the supervision of a physician, is very expensive ($1,200 to $3,500 per month), and appears to have several negative side effects.
Doctor's Triple Strength Growth Hormone utilizes a very rare herbal extract known as Mucuna Pruriens from India. Mucuna Pruriens, also know as Velvetbean, has an unusually high content of naturally occurring L-dopa. Fountain of Youth's special extraction process further upgrades higher levels of L-dopa. (Mucuna Pruriens from other areas of the world is much less potent.)
L-dopa, is remarkable. L-dopa is the world’s most extensively researched amino acid. L-dopa for the past 30 years has been the world’s best known and most widely used prescription for the treatment of the dreadful dopamine deficiency disease called Parkinson’s. L-dopa is one of the few substances that crosses the blood brain barrier and converts into Dopamine. Dopamine is a very powerful neurotransmitter that stimulates the hypothalamus and pituitary to release growth hormone. Dopamine also regulates motor control, sex drive, immune function, fat gain and loss, lean muscle gain, bone density, energy levels, and the ability to sleep soundly.
Between the ages of 30 to 40, dopamine containing neurons in the human brain begin declining. This is a universal characteristic of the aging process. A shocking epidemic of brain dopamine neuron deficiency is now occurring in much younger men and women. This chemical toxicity is believed to be attributed to the worldwide use of pesticides, insecticides, cleaning products and supplies, synthetic clothes, plastics, chemical toxins, environmental pollutants, and additives in processed foods.
The second herb used in Triple Strength Growth Hormone is the Ayurvedic herb Tribulus Terrestris. This herb, also known as Gokshura, has active components known as saponins and alkaloids, that are very potent luteinizing agents. Fountain of Youth's special extraction process upgrades the levels of these components.
Triple Strength Growth Hormone contains a unique blend of both Tribulus Terrestris extract, and the natural Tribulus Terrestris herb. The herb, unlike the more potent extract, contains important phytonutrients. This special blend of Tribulus Terrestris is widely used in India to balance and boost the body’s ability to maintain natural hormone levels. Herbalists use Tribulus Terrestris for the endocrine system to assist hormone production largely due to its action on the liver. It acts as a liver tonic, improving the emulsification of fats to essential fatty acids, which allows the good HDL cholesterol, to be used by the liver to manufacture hormones. It also helps prevent the body from losing L-dopa by retaining dopamine uptake in the system for long periods of time. This synergistic combination of herbs also helps to block the release of Somatostatin, the antagonistic hormone that causes the body to lower growth hormone levels.
The one major problem that has faced all oral growth hormone products is the destructive effect of stomach acids on active ingredients and L-dopa. Stomach acid renders most growth hormone active ingredients and L-dopa virtually ineffective.
Triple Strength Growth Hormone is rated number one by leading industry experts. This remarkable patented formula is the only product listed under GROWTH HORMONE THERAPY, page 713 in the world renowned manual “Prescription for Nutritional Healing” by Phyllis A. Balch, CNC and James F. Balch, M.D. (3rd Edition). “Prescription for Nutritional Healing” is considered by the industry as the most factual, exacting, and reputable natural health manual available.Buy Doctor’s Growth Hormone Supplements here at a fraction of the cost of which most growth hormone supplements cost.
What is Growth Hormone?
Growth hormone (GH or HGH), also known as somatotropin or somatropin, is a peptide hormone that stimulates growth, cell reproduction and regeneration in humans and other animals. It is a type of mitogen which is specific only to certain kinds of cells. Growth hormone (GH) is a 191-amino acid, single-chainpolypeptide that is synthesized, stored, and secreted by somatotropic cells within the lateral wings of the anterior pituitary gland.
HGH, produced by the pituitary gland, spurs growth in children and adolescents. It also helps to regulate body composition, body fluids, muscle and bone growth, sugar and fat metabolism, and possibly heart function. Produced synthetically, HGH is the active ingredient in a number of prescription drugs and in other products available widely over the Internet.
Growth hormone (GH l) is also called somatotropin (British: somatotrophin). The human form of growth hormone is known as human growth hormone, or hGH (ovine growth hormone, or sheep growth hormone, is abbreviated oGH). GH can refer either to the natural hormone produced by the pituitary (somatotropin), or biosynthetic GH for therapy.
Cadaver growth hormone is the term for GH extracted from the pituitary glands of human cadavers between 1960 and 1985 for therapy of deficient children. In the U.S., cadaver GH, also referred to as NPA growth hormone, was provided by the National Pituitary Agency, and by other national programs and commercial firms as well. In 1985 it was associated with the development of Creutzfeldt-Jakob Disease, and was withdrawn from use.
rHGH refers to recombinant human growth hormone (somatropin). Its amino acid sequence is identical with that of endogenous human GH.
It is coincidental that rHGH also refers to rhesus monkey GH, using the accepted naming convention. Rhesus growth hormone was never used by physicians to treat human patients, but rhesus GH was part of the lore of the underground anabolic steroid community in those years, and fraudulent versions may have been bought and sold in gyms.
met-GH refers to methionyl-growth hormone. This was the first recombinant GH product marketed (Protropin by Genentech). It had the same amino acidsequence as human GH with an extra methionine at the end of the chain to facilitate the manufacturing process. It was discontinued in 2004.
rBST refers to recombinant bovine somatropin (cow growth hormone), or recombinant bovine GH (rbGH).
Growth Hormone (GH) is a stress hormone that raises the concentration of glucose and free fatty acids. It stimulates IGF which raises proteins.
Growth Hormone (GH) is used as a prescription drug in medicine to treat children's growth disorders and adult growth hormone (GH) deficiency. In the United States, it is only available legally from pharmacies, by prescription from a doctor. In recent years in the United States, some doctors have started to prescribe growth hormone in GH-deficient older patients to increase vitality.
In its role as an anabolic agent, Human Growth Hormone (HGH) has been abused by competitors in sports at least since 1982, and it has been banned by the IOCand NCAA. Traditional urine analysis could not detect doping with Human Growth Hormone (HGH), so the ban was unenforceable until the early 2000s whenblood tests that could distinguish between natural and artificial Human Growth Hormone (HGH) were starting to be developed. Blood tests conducted by WADAat the 2004 Olympic Games in Athens, Greece targeted primarily Human Growth Hormone (HGH). This use for the drug is not approved by the FDA.
Somatotropin (STH) refers to the growth hormone produced naturally in animals and extracted from carcasses. Hormone extracted from human cadavers is abbreviated hGH. The growth hormone produced by recombinant DNA technology has the approved generic name somatropin and the brand name Humatrope, and is properly abbreviated rhGH in the scientific literature. Since its introduction in 1992 Humatrope has been a banned sports doping agent, and in this context is referred to as Human Growth Hormone (HGH).
Genes for human growth hormone, known as growth hormone 1 (somatotropin) and growth hormone 2, are localized in the q22-24 region of chromosome 17 and are closely related to human chorionic somatomammotropin (also known as placental lactogen) genes. Growth Hormone (GH), human chorionic somatomammotropin, and prolactin belong to a group of homologous hormones with growth-promoting and lactogenic activity.
The major isoform of the human growth hormone is a protein of 191 amino acids and a molecular weight of 22,124 daltons. The structure includes four helices necessary for functional interaction with the GH receptor. It appears that, in structure, GH is evolutionarily homologous to prolactin and chorionic somatomammotropin. Despite marked structural similarities between growth hormone from different species, only human and Old World monkey growth hormones have significant effects on the human growth hormone receptor.
Several molecular isoforms of Growth Hormone (GH) exist in the pituitary gland and are released to blood. In particular, a variant of approximately 20 kDa originated by an alternative splicing is present in a rather constant 1:9 ratio, while recently an additional variant of ~ 23-24 kDa has also been reported in post-exercise states at higher proportions. This variant has not been identified, but it has been suggested to coincide with a 22 kDa glycosylated variant of 23 kDa identified in the pituitary gland. Furthermore, these variants circulate partially bound to a protein (growth hormone-binding protein, GHBP), which is the truncated part of the growth hormone receptor, and an acid-labile subunit (ALS).
Secretion of growth hormone (GH) in the pituitary is regulated by the neurosecretory nuclei of the hypothalamus. These cells release the peptides Growth hormone-releasing hormone (GHRH or somatocrinin) and Growth hormone-inhibiting hormone (GHIH or somatostatin) into the hypophyseal portal venous blood surrounding the pituitary. GH release in the pituitary is primarily determined by the balance of these two peptides, which in turn is affected by many physiological stimulators (e.g., exercise, nutrition, sleep) and inhibitors (e.g., free fatty acids) of GH secretion.
Somatotropic cells in the anterior pituitary gland then synthesize and secrete GH in a pulsatile manner, in response to these stimuli by the hypothalamus. The largest and most predictable of these GH peaks occurs about an hour after onset of sleep with plasma levels of 13 to 72 ng/mL. Otherwise there is wide variation between days and individuals. Nearly fifty percent of GH secretion occurs during the third and fourth NREM sleep stages. Surges of secretion during the day occur at 3- to 5-hour intervals. The plasma concentration of GH during these peaks may range from 5 to even 45 ng/mL. Between the peaks, basal GH levels are low, usually less than 5 ng/mL for most of the day and night. Additional analysis of the pulsatile profile of GH described in all cases less than 1 ng/ml for basal levels while maximum peaks were situated around 10-20 ng/mL.
A number of factors are known to affect GH secretion, such as age, sex, diet, exercise, stress, and other hormones. Young adolescents secrete GH at the rate of about 700 μg/day, while healthy adults secrete GH at the rate of about 400 μg/day. Sleep deprivation generally suppresses GH release, particularly after early adulthood.
Stimulators of growth hormone (GH) secretion include:
-peptide hormones=GHRH (somatocrinin) through binding to the growth hormone-releasing hormone receptor, (GHRHR), ghrelin through binding to growth hormone secretagogue receptors (GHSR).
-sex hormones= increased androgen secretion during puberty (in males from testis and in females from adrenal cortex), estrogen.
-clonidine and L-DOPA by stimulating GHRH release.
-α4β2 nicotinic agonists, including nicotine, which also act synergistically with clonidine.
-hypoglycemia, arginine and propranolol by inhibiting somatostatin release.
-deep sleep, niacin as nicotinic acid (Vitamin B3), fasting, vigorous exercise
Inhibitors of GH secretion include: GHIH (somatostatin) from the periventricular nucleus, circulating concentrations of GH and IGF-1 (negative feedback on the pituitary and hypothalamus), hyperglycemia, glucocorticoids, dihydrotestosterone.
In addition to control by endogenous and stimulus processes, a number of foreign compounds (xenobiotics such as drugs and endocrine disruptors) are known to influence GH secretion and function.
Main pathways in endocrine regulation of growth.
Effects of growth hormone on the tissues of the body can generally be described as anabolic (building up). Like most other protein hormones, growth hormone (GH) acts by interacting with a specific receptor on the surface of cells.
Increased height during childhood is the most widely known effect of growth hormone (GH). Height appears to be stimulated by at least two mechanisms:
Because polypeptide hormones are not fat-soluble, they cannot penetrate cell membranes. Thus, GH exerts some of its effects by binding to receptors on target cells, where it activates the MAPK/ERK pathway. Through this mechanism GH directly stimulates division and multiplication of chondrocytes of cartilage.
GH also stimulates, through the JAK-STAT signaling pathway, the production of insulin-like growth factor 1 (IGF-1, formerly known as somatomedin C), a hormone homologous to proinsulin. The liver is a major target organ of GH for this process and is the principal site of IGF-1 production. IGF-1 has growth-stimulating effects on a wide variety of tissues. Additional IGF-1 is generated within target tissues, making it what appears to be both an endocrine and anautocrine/paracrine hormone. IGF-1 also has stimulatory effects on osteoblast and chondrocyte activity to promote bone growth.
In addition to increasing height in children and adolescents, growth hormone has many other effects on the body:
Increases calcium retention, and strengthens and increases the mineralization of bone
Increases muscle mass through sarcomere hypertrophy
Increases protein synthesis
Stimulates the growth of all internal organs excluding the brain
Plays a role in homeostasis
Reduces liver uptake of glucose
Promotes gluconeogenesis in the liver
Contributes to the maintenance and function of pancreatic islets
Stimulates the immune system
Increases deiodination of T4 to T3
The most common disease of growth hormone (GH) excess is a pituitary tumor composed of somatotroph cells of the anterior pituitary. These somatotrophadenomas are benign and grow slowly, gradually producing more and more growth hormone (GH). For years, the principal clinical problems are those of GH excess. Eventually, the adenoma may become large enough to cause headaches, impair vision by pressure on the optic nerves, or cause deficiency of other pituitary hormones by displacement.
Prolonged GH excess thickens the bones of the jaw, fingers and toes. Resulting heaviness of the jaw and increased size of digits is referred to as acromegaly. Accompanying problems can include sweating, pressure on nerves (e.g., carpal tunnel syndrome), muscle weakness, excess sex hormone-binding globulin (SHBG), insulin resistance or even a rare form of type 2 diabetes, and reduced sexual function.
GH-secreting tumors are typically recognized in the fifth decade of life. It is extremely rare for such a tumor to occur in childhood, but, when it does, the excessive GH can cause excessive growth, traditionally referred to as pituitary gigantism.
Surgical removal is the usual treatment for GH-producing tumors. In some circumstances, focused radiation or a GH antagonist such as pegvisomant may be employed to shrink the tumor or block function. Other drugs like octreotide (somatostatin agonist) and bromocriptine (dopamine agonist) can be used to block GH secretion because both somatostatin and dopamine negatively inhibit GHRH-mediated GH release from the anterior pituitary.
Growth hormone deficiency
The effects of growth hormone deficiency vary depending on the age at which they occur. In children, growth failure and short stature are the major manifestations of GH deficiency, with common causes including genetic conditions and congenital malformations. It can also cause delayed sexual maturity. In adults, deficiency is rare, with the most common cause a pituitary adenoma, and others including a continuation of a childhood problem, other structural lesions or trauma, and very rarely idiopathic GHD.
Adults with GHD "tend to have a relative increase in fat mass and a relative decrease in muscle mass and, in many instances, decreased energy and quality of life".
Diagnosis of GH deficiency involves a multiple-step diagnostic process, usually culminating in GH stimulation tests to see if the patient's pituitary gland will release a pulse of GH when provoked by various stimuli.
As a medication
Growth hormone treatment
Treatment with exogenous GH is indicated only in limited circumstances, and needs regular monitoring due to the frequency and severity of side-effects. GH is used as replacement therapy in adults with GH deficiency of either childhood-onset or adult-onset (usually as a result of an acquired pituitary tumor). In these patients, benefits have variably included reduced fat mass, increased lean mass, increased bone density, improved lipid profile, reduced cardiovascular risk factors, and improved psychosocial well-being.
Other approved uses
Growth Hormone (GH) can be used to treat conditions that produce short stature but are not related to deficiencies in GH. However, results are not as dramatic when compared to short stature that is solely attributable to deficiency of GH. Examples of other causes of shortness often treated with GH are Turner syndrome,chronic renal failure, Prader–Willi syndrome, intrauterine growth retardation, and severe idiopathic short stature. Higher ("pharmacologic") doses are required to produce significant acceleration of growth in these conditions, producing blood levels well above normal ("physiologic"). Despite the higher doses, side-effects during treatment are rare, and vary little according to the condition being treated.
One version of rHGH has also been FDA approved for maintaining muscle mass in wasting due to AIDS.
Physicians are free to prescribe GH off-label for other uses. However, the efficacy and safety of off-label uses of GH are unknown as these have not been tested in a double-blinded clinical trial.
In recent years in the United States, some doctors have started to prescribe growth hormone in GH-deficient older patients (but not on healthy people) to increase vitality. While legal, the efficacy and safety of this use for HGH has not been tested in a clinical trial. At this time, hGH is still considered a very complex hormone, and many of its functions are still unknown.
GH has also been used experimentally to treat multiple sclerosis, to enhance weight loss in obesity, as well as in fibromyalgia, heart failure, Crohn's disease andulcerative colitis, and burns. GH has also been used experimentally in patients with short bowel syndrome to lessen the requirement for intravenous total parenteral nutrition.
Side-effects of Growth Hormone (GH)
Use of GH as a drug has been approved by the FDA for several indications. This means that the drug has acceptable safety in light of its benefits when used in the approved way. Like every drug, there are several side effects caused by GH, some common, some rare. Injection-site reaction is common. More rarely, patients can experience joint swelling, joint pain, carpal tunnel syndrome, and an increased risk of diabetes. In some cases, the patient can produce an immune response against growth hormone (GH). GH may also be a risk factor for Hodgkin's lymphoma.
One survey of adults that had been treated with replacement cadaver GH (which has not been used anywhere in the world since 1985) during childhood showed a mildly increased incidence of colon cancer and prostate cancer, but linkage with the GH treatment was not established.
Growth Hormone on performance enhancement
Growth hormone in sports
The first description of the use of GH as a doping agent was Dan Duchaine’s “Underground Steroid handbook” which emerged from California in 1982; it is not known where and when GH was first used this way.
Athletes in many sports have used human growth hormone (HGH) in order to attempt to enhance their athletic performance. Some recent studies have not been able to support claims that human growth hormone can improve the athletic performance of professional male athletes. Many athletic societies ban the use of GH and will issue sanctions against athletes who are caught using it. In the United States, GH is legally available only by prescription from a medical doctor.
Drug development history
Growth hormone treatment
The identification, purification and later synthesis of growth hormone is associated with Choh Hao Li. Genentech pioneered the first use of recombinant human growth hormone for human therapy in 1981.
Prior to its production by recombinant DNA technology, growth hormone used to treat deficiencies was extracted from the pituitary glands of cadavers. Attempts to create a wholly synthetic HGH failed. Limited supplies of HGH resulted in the restriction of HGH therapy to the treatment of idiopathic short stature. Very limited clinical studies of growth hormone derived from an old world monkey, the Rhesus macaque, were conducted by John C. Beck and colleagues in Montreal, in the late 1950s. The study published in 1957, which was conducted on "a 13-year-old male with well-documented hypopituitarism secondary to a crainiophyaryngioma," found that: "Human and monkey growth hormone resulted in a significant enhancement of nitrogen storage...(and) there was a retention of potassium, phosphorus, calcium, and sodium. ...There was a gain in body weight during both periods.... There was a significant increase in urinary excretion of aldosterone during both periods of administration of growth hormone. This was most marked with the human growth hormone.... Impairment of the glucose tolerance curve was evident after 10 days of administration of the human growth hormone. No change in glucose tolerance was demonstrable on the fifth day of administration of monkey growth hormone." The other study, published in 1958, was conducted on six people: the same subject as the Science paper; an 18 year old male with statural and sexual retardation and a skeletal age of between 13 and 14 years; a 15 year old female with well documented hypopituitarism secondary to a craniopharyngioma; a 53 year old female with carcinoma of the breast and widespread skeletal metastases; a 68 year old female with advanced postmenopausal osteoporosis; and a healthy 24 year old medical student without any clinical or laboratory evidence of systemic disease.
In 1985, unusual cases of Creutzfeldt-Jacob disease were found in individuals that had received cadaver-derived HGH ten to fifteen years previously. Based on the assumption that infectious prions causing the disease were transferred along with the cadaver-derived HGH, cadaver-derived HGH was removed from the market.
In 1985, biosynthetic human growth hormone replaced pituitary-derived human growth hormone for therapeutic use in the U.S. and elsewhere.
As of 2005, recombinant growth hormones available in the United States (and their manufacturers) included Nutropin (Genentech), Humatrope (Lilly), Genotropin (Pfizer), Norditropin (Novo), and Saizen (Merck Serono). In 2006, the U.S. Food and Drug Administration (FDA) approved a version of rHGHcalled Omnitrope (Sandoz). A sustained-release form of growth hormone, Nutropin Depot (Genentech and Alkermes) was approved by the FDA in 1999, allowing for fewer injections (every 2 or 4 weeks instead of daily); however, the product was discontinued by Genentech/Alkermes in 2004 for financial reasons (Nutropin Depot required significantly more resources to produce than the rest of the Nutropin line).
Herbal Human Growth Hormone Supplements
The Human Growth Hormone, (HGH) is naturally produced by our pituitary gland. It is what causes us to grow and mature as we get older. However, our HGH levels decrease as we age. Beginning in our 20's, and by the time we are in our 40's it has declined to about 80% of its original production. This may be a normal decline, but as we know, there are many things that happen when we age that we would like to prevent, or at least avoid for as long as possible. Using an Herbal Human Growth Hormone may be one thing that could help us achieve longevity and restore a youthful appearance and vitality.
Using an Herbal Human Growth Hormone is easy and inexpensive.
An Herbal Human Growth Hormone is usually taken in the form of a 'releaser'. This is a supplement that is not Human Growth Hormone, but a combination of herbs that are known to work together to encourage your pituitary gland to produce Human Growth Hormone as it once did. The releaser is taken at bedtime, and works while you sleep.
There are other forms of Human Growth Hormone replacement, but these are synthetic and may cause many side effects that you won't get from an herbal Growth Hormone.
There may be many benefits to using an Herbal Human Growth Hormone.
Some of these benefits are simply the result of HGH being used to slow down the aging process. Others may be repair of the effects of aging you have already experienced. Increased muscle mass, improved memory, less mood swings, more youthful appearance, including less wrinkles and smoother skin, are some of the things you may notice happening to you as your body produces more Human Growth Hormone.
Herbs to Increase HGH
In childhood, the body produces HGH, or human growth hormone, to spur musculoskeletal growth. It produces increasingly more of this growth hormone until peaking when the body experiences its growth spurt in puberty. After puberty, growth hormone levels and production gradually decline, with HGH adopting a lesser biochemical role, helping maintain organ and tissue health. In later years, HGH production declines considerably. This may contribute to decreased bone density and muscle mass, increased body fat and other body changes associated with aging. While scientists debate whether direct HGH supplementation has any measurable effects on signs of aging, many herbalists and sports nutritionists promote the use of herbs that stimulate the body's production of HGH as an alternative approach to combating signs of aging and enhancing body mass, strength and performance. Before trying any of these herbal therapies yourself, discuss your intentions with your doctor to make sure that it's safe for you.
Herbs that may raise growth hormone levels
HGH is produced by the pituitary gland, which is located in the brain. Certain neurotransmitters like dopamine and norepinephrine produced by the hypothalamus gland, also in the brain, promote the pituitary's production and release of HGH. As described in a 2007 review of research in "Clinical Interventions in Aging", an age-related decline in the production of these neurotransmitters may be involved in a similar decline in HGH production. Among the herbal therapies the paper's author, Richard F. Walker, recommends to counteract this age-related hormone insufficiency are mucuna prurien, or velvet bean. It acts in the body as a precursor to dopamine and norepinephrine and promotes their increased production.
In the same 2007 "Clinical Interventions in Aging" research review, monoamine oxidase (MAO) inhibitors were cited as reducing turnover of the neurotransmitters dopamine and norepinephrine, thereby reducing, delaying or preventing the pituitary's age-related decline in HGH production. Walker lists gingko biloba as one herbal therapy high in these MAO inhibitors. Doctors advise caution in taking any MAO inhibitor if already taking prescribed MAOI anti-depressant medications.
More commonly known as horny goat weed, herba epimedium also has MAO inhibiting effects. One study on the effects of epimedium and four other so-called yang strengthening Chinese herbs with MAO inhibiting properties on the production of certain neurotransmitters in the hypothalamus glands of rats found that all five herbs increased levels of dopamine, norepinephrine and other pituitary-stimulating neurotransmitters. The other yang-strengthening herbs studied that also exhibited MAO inhibiting properties were cinamomi, cortex, herba cistanchis and radix aconiti praeparata
Mucuna prurien is a medicinal herb that helps increase the level of the Human Growth Hormone. It has been used extensively by the Indian physicians and doctors. Research is suggestive of the fact that, Mucuna prurien has a very high nutritional value. It consists of almost 22 - 29 % of crude oil, 6 - 7 % crude lipid, 50 - 55 % carbohydrates and 8 % dietary fiber. Mucuna prurien has been used to manage imbalances of the Growth Hormone, in a natural way.
Ginseng is a wonderful herb, commonly administered to boost energy levels. Ginseng helps enhance the release HGH throughout the body, and peps up energy levels and suffuses you with vitality. It increase the overall body performance, reduces stress, fatigue and exhaustion. However, an overdose of this herbal preparation has shown to cause anxiety, depression and irritability.
This powerful herb increases the secretion of HGH by acting on the Pituitary gland. Research and laboratory findings have proved it to be highly effective in the optimal functioning of the Pituitary gland. Agnus Castus is the most frequently used herb to regulate and regularize the hormonal profile in the body.
Ginkgo Biloba has an extraordinary ability to augment blood circulation and oxygen levels in the brain tissue, Pituitary gland and cerebral areas. Ginkgo also increases the brain’s electrical activity, and prevents a platelet build-up inside arterial
Ranabir S, Reetu K (January 2011). "Stress and hormones". Indian J Endocrinol Metab 15 (1): 18–22. doi:10.4103/2230-8210.77573.PMC 3079864. PMID 21584161.
Greenwood FC, Landon J (April 1966). "Growth hormone secretion in response to stress in man". Nature 210 (5035): 540–1. doi:10.1038/210540a0.PMID 5960526.
Powers M (2005). "Performance-Enhancing Drugs". In Leaver-Dunn D, Houglum J, Harrelson GL. Principles of Pharmacology for Athletic Trainers. Slack Incorporated. pp. 331–332. ISBN 1-55642-594-5.
Daniels ME (1992). "Lilly's Humatrope Experience". Nature Biotechnology 10 (7): 812. doi:10.1038/nbt0792-812a.
Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P (July 2006). "Human growth hormone doping in sport". Br J Sports Med. 40 Suppl 1: i35–9. doi:10.1136/bjsm.2006.027573. PMC 2657499. PMID 16799101.
"GH1 growth hormone 1 (Homo sapiens) - Gene". National Center for Biotechnology Information, U.S. National Library of Medicine.
"GH2 growth hormone 2 (Homo sapiens) - Gene". National Center for Biotechnology Information, U.S. National Library of Medicine.
Yi S, Bernat B, Pál G, Kossiakoff A, Li WH (July 2002). "Functional promiscuity of squirrel monkey growth hormone receptor toward both primate and nonprimate growth hormones". Mol. Biol. Evol. 19 (7): 1083–92. doi:10.1093/oxfordjournals.molbev.a004166. PMID 12082127.
Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD, Ho KK (October 2002). "Physiological and pharmacological regulation of 20-kDa growth hormone". Am. J. Physiol. Endocrinol. Metab. 283 (4): E836–43. doi:10.1152/ajpendo.00122.2002. PMID 12217902.
Kohler M, Püschel K, Sakharov D, Tonevitskiy A, Schänzer W, Thevis M (November 2008). "Detection of recombinant growth hormone in human plasma by a 2-D PAGE method". Electrophoresis 29 (22): 4495–502. doi:10.1002/elps.200800221. PMID 19003817.
Bustamante JJ, Gonzalez L, Carroll CA, Weintraub ST, Aguilar RM, Muñoz J, Martinez AO, Haro LS (July 2009). "O-Glycosylated 24-kDa human growth hormone (hGH) has a mucin-like biantennary disialylated tetrasaccharide attached at Thr-60". Proteomics 9 (13): 3474–88.doi:10.1002/pmic.200800989. PMC 2904392. PMID 19579232.
Bartholomew EF, Martini F, Nath JL (2009). Fundamentals of anatomy & physiology. Upper Saddle River, NJ: Pearson Education Inc. pp. 616–617.ISBN 0-321-53910-9.
Takahashi Y, Kipnis D, Daughaday W (1968). "Growth hormone secretion during sleep". J Clin Invest 47 (9): 2079–90.doi:10.1172/JCI105893. PMC 297368. PMID 5675428.
Mehta A, Hindmarsh PC (2002). "The use of somatropin (recombinant growth hormone) in children of short stature". Paediatr Drugs 4 (1): 37–47.PMID 11817985.
Natelson BH, Holaday J, Meyerhoff J, Stokes PE (August 1975). "Temporal changes in growth hormone, cortisol, and glucose: relation to light onset and behavior". Am. J. Physiol. 229 (2): 409–15. PMID 808970.
Nindl BC, Hymer WC, Deaver DR, Kraemer WJ (July 2001). "Growth hormone pulsatility profile characteristics following acute heavy resistance exercise". J. Appl. Physiol. 91 (1): 163–72. PMID 11408427.
Juul A, Jørgensen JO, Christiansen JS, Müller J, Skakkeboek NE (1995). "Metabolic effects of GH: a rationale for continued GH treatment of GH-deficient adults after cessation of linear growth". Horm. Res. 44 Suppl 3 (3): 64–72. doi:10.1159/000184676. PMID 8719443.
Gardner DG, Shoback D (2007). Greenspan's Basic and Clinical Endocrinology (8th ed.). New York: McGraw-Hill Medical. pp. 193–201.ISBN 0-07-144011-9.
Mullington J, Hermann D, Holsboer F, Pollmächer T (September 1996). "Age-dependent suppression of nocturnal growth hormone levels during sleep deprivation". Neuroendocrinology 64 (3): 233–41. doi:10.1159/000127122. PMID 8875441.
Lin-Su K, Wajnrajch MP (December 2002). "Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor". Rev Endocr Metab Disord 3(4): 313–23. doi:10.1023/A:1020949507265. PMID 12424433.
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR (November 2000). "The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion". Endocrinology 141 (11): 4325–8.doi:10.1210/en.141.11.4325. PMID 11089570.
Meinhardt UJ, Ho KK (October 2006). "Modulation of growth hormone action by sex steroids". Clin. Endocrinol. (Oxf) 65 (4): 413–22.doi:10.1111/j.1365-2265.2006.02676.x. PMID 16984231.
Low LC (1991). "Growth hormone-releasing hormone: clinical studies and therapeutic aspects". Neuroendocrinology. 53 Suppl 1: 37–40.doi:10.1159/000125793. PMID 1901390.
Fedi M, Bach LA, Berkovic SF, Willoughby JO, Scheffer IE, Reutens DC (February 2008). "Association of a nicotinic receptor mutation with reduced height and blunted physostigmine-stimulated growth hormone release". J. Clin. Endocrinol. Metab. 93 (2): 634–7. doi:10.1210/jc.2007-1611.PMID 18042647.
Wilkins JN, Carlson HE, Van Vunakis H, Hill MA, Gritz E, Jarvik ME (1982). "Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers". Psychopharmacology (Berl.) 78 (4): 305–8. doi:10.1007/BF00433730. PMID 6818588.
Coiro V, d'Amato L, Borciani E, Rossi G, Camellini L, Maffei ML, Pignatti D, Chiodera P (November 1984). "Nicotine from cigarette smoking enhances clonidine-induced increase of serum growth hormone concentrations in men". Br J Clin Pharmacol 18 (5): 802–5. doi:10.1111/j.1365-2125.1984.tb02547.x. PMC 1463553. PMID 6508989.
Alba-Roth J, Müller OA, Schopohl J, von Werder K (December 1988). "Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion". J. Clin. Endocrinol. Metab. 67 (6): 1186–9. doi:10.1210/jcem-67-6-1186. PMID 2903866.
Van Cauter E, Latta F, Nedeltcheva A, Spiegel K, Leproult R, Vandenbril C, Weiss R, Mockel J, Legros JJ, Copinschi G (June 2004). "Reciprocal interactions between the GH axis and sleep". Growth Horm. IGF Res. 14 Suppl A: S10–7. doi:10.1016/j.ghir.2004.03.006. PMID 15135771.
Quabbe HJ, Luyckx AS, L'age M, Schwarz C (August 1983). "Growth hormone, cortisol, and glucagon concentrations during plasma free fatty acid depression: different effects of nicotinic acid and an adenosine derivative (BM 11.189)". J. Clin. Endocrinol. Metab. 57 (2): 410–4. doi:10.1210/jcem-57-2-410.PMID 6345570.
Nørrelund H (April 2005). "The metabolic role of growth hormone in humans with particular reference to fasting". Growth Horm. IGF Res. 15 (2): 95–122. doi:10.1016/j.ghir.2005.02.005. PMID 15809014.
Kanaley JA, Weltman JY, Veldhuis JD, Rogol AD, Hartman ML, Weltman A (November 1997). "Human growth hormone response to repeated bouts of aerobic exercise". J. Appl. Physiol. 83 (5): 1756–61. PMID 9375348.
Guillemin R, Gerich JE (1976). "Somatostatin: physiological and clinical significance". Annu. Rev. Med. 27: 379–88.doi:10.1146/annurev.me.27.020176.002115. PMID 779605.
Allen DB (September 1996). "Growth suppression by glucocorticoid therapy". Endocrinol. Metab. Clin. North Am. 25 (3): 699–717.doi:10.1016/S0889-8529(05)70348-0. PMID 8879994.
Scarth JP (2006). "Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review". Xenobiotica 36 (2–3): 119–218. doi:10.1080/00498250600621627. PMID 16702112.
Binder G, Wittekindt N, Ranke MB (February 2007). "Noonan Syndrome: Genetics and Responsiveness to Growth Hormone Therapy". Horm Res 67 (Supplement 1): 45–49. doi:10.1159/000097552. ISBN 978-3-8055-8255-1.
"Actions of Anterior Pituitary Hormones: Physiologic Actions of GH". Medical College of Georgia. 2007. Retrieved 2008-01-16.
King MW (2006). "Structure and Function of Hormones: Growth Hormone". Indiana State University. Retrieved 2008-01-16.
T.F. Davies (ed.), A Case-Based Guide to Clinical Endocrinology, 2008, pag.16
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society's Clinical Guidelines Subcommittee, Stephens PA (May 2006). "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline". J. Clin. Endocrino. Metab. 91 (5): 1621–34. doi:10.1210/jc.2005-2227. PMID 16636129.
Gilden D (January 1995). "Human growth hormone available for AIDS wasting". GMHC Treat Issues 9 (1): 9–11. PMID 11367383.
Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE (July 1990). "Effects of human growth hormone in men over 60 years old". N. Engl. J. Med. 323 (1): 1–6. doi:10.1056/NEJM199007053230101. PMID 2355952.
Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR (January 2007). "Systematic review: the safety and efficacy of growth hormone in the healthy elderly". Ann. Intern. Med. 146 (2): 104–15. doi:10.7326/0003-4819-146-2-200701160-00005. PMID 17227934.
"No proof that growth hormone therapy makes you live longer, study finds". PhysOrg.com. 2007-01-16. Retrieved 2009-03-16.
Stephen Barrett, M.D. Growth Hormone Schemes and Scams
Kuczynski A (1998-04-12). "Anti-Aging Potion or Poison?". New York Times.
Freedman RJ, Malkovska V, LeRoith D, Collins MT (October 2005). "Hodgkin lymphoma in temporal association with growth hormone replacement". Endocr. J. 52 (5): 571–5. doi:10.1507/endocrj.52.571. PMID 16284435.
Swerdlow AJ, Higgins CD, Adlard P, Preece MA (July 2002). "Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study". Lancet 360 (9329): 273–7. doi:10.1016/S0140-6736(02)09519-3. PMID 12147369.
Holt RI, Erotokritou-Mulligan I, Sönksen PH (August 2009). "The history of doping and growth hormone abuse in sport". Growth Horm. IGF Res.19 (4): 320–6. doi:10.1016/j.ghir.2009.04.009. PMID 19467612.
Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, Bendavid E, Saynina O, Salpeter SR, Garber AM, Hoffman AR (May 2008). "Systematic review: the effects of growth hormone on athletic performance". Ann. Intern. Med. 148 (10): 747–58. doi:10.7326/0003-4819-148-10-200805200-00215. PMID 18347346.
Randall T (2008-03-17). "Athletes Don't Benefit From Human Growth Hormone, Study Finds". Bloomberg. Retrieved 2011-08-28.
Gaffney G (2008-03-17). "Steroid Nation: Review from Stanford says HGH no benefit as PED". Steroid Nation. Retrieved 2011-08-28.
Singleton ER (2010-06-04). "Atlas Operations, Inc.". Warning Letter. U.S. Food and Drug Administration. Retrieved 2011-08-28.
"Chicken from Farm to Table | USDA Food Safety and Inspection Service". Fsis.usda.gov. 2011-04-06. Retrieved 2011-08-26.
"Poultry Industry Frequently Asked Questions". U.S Poultry & Egg Association. Retrieved June 21, 2012.
"Landline - 5/05/2002: Challenging food safety myths . Australian Broadcasting Corp". Abc.net.au. 2002-05-05. Retrieved 2011-08-26.
"Center for Veterinary Medicine Master" (pdf). www.fda.gov. 2011-04-06. Retrieved 2011-08-28.
"Growth Promoters in Animal Production" (pdf). 2006. Retrieved 2011-08-28.
Maybe, Nancy G (1984). "Direct expression of human growth in Escherichia coli with the lipoprotein promoter". In Arthur P. Bollon. Recombinant DNA products: insulin, interferon, and growth hormone. Boca Raton: CRC Press. ISBN 0-8493-5542-7.
Beck JC, Mcgarry EE, Dyrenfurth I, Venning EH (May 1957). "Metabolic effects of human and monkey growth hormone in man". Science 125(3253): 884–5. doi:10.1126/science.125.3253.884. PMID 13421688.
Beck JC, Mcgarry EE, Dyrenfurth I, Venning EH (November 1958). "The metabolic effects of human and monkey growth hormone in man". Ann. Intern. Med. 49 (5): 1090–105. doi:10.7326/0003-4819-49-5-1090. PMID 13595475.
"Genentech and Alkermes Announce Decision to Discontinue Commercialization of Nutropin Depot". Press Release. Business Wire. 2004-06-01. Retrieved 2011-08-28.
Information above is based on years of experience by professional colleagues, doctors, herbal healers, drug-free practiners, scientists and research conducted throughout the world, with extensive review of scientific literature and new clinical discoveries. Listed information is solely intended to be used for educational purposes only and is not intended as a basis for diagnosis, treatment, or to cure any disease. No medical claims, systemic administration claims are made, nor implied for the use of any of the information used above. These statements have not been evaluated by the US Food and Drug Administration (FDA).